TITLE

Promoting angiogenesis to a fault

AUTHOR(S)
Hicklin, Daniel J
PUB. DATE
March 2007
SOURCE
Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p300
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a research to identify additional angiogenic pathways that could be targeted for cancer therapy. The Delta-like ligand/Notch signaling pathway is a regulator of tumor angiogenesis. The inactivation of the pathway was found to inhibit tumors by promoting the growth of defective vessels.
ACCESSION #
24279315

 

Related Articles

  • The impact of anti-angiogenic agents on cancer therapy. Marmé, Dieter // Journal of Cancer Research & Clinical Oncology;Nov2003, Vol. 129 Issue 11, p607 

    The article focuses on the impact of anti-angiogenic agents on cancer therapy. A functioning vascular network is crucial for the survival and growth of solid tumors. This makes tumor blood vessels a key target for drug discovery in oncology. A prerequisite for these approaches is the precise...

  • Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Langenkamp, Elise; Molema, Grietje // Cell & Tissue Research;Dec2008, Vol. 335 Issue 1, p205 

    Microvascular endothelial cells display a large degree of heterogeneity in function depending on their location in the vascular tree. The existence of organ-specific, microvascular-bed-specific, and even intravascular variations in endothelial cell gene expression emphasizes their high...

  • Angiogenic Inhibitors: Role In The Cancer Treatment. Desai, Devenkumar V.; Bindi, Shukla; Kapoor, Amit; Yeluri, Sashidhar; Saxena, Mohit // Internet Journal of Oncology;2004, Vol. 2 Issue 1, p1 

    Angiogenesis is one of the basic important mechanisms for the tumor growth. Tumor cells produce these angiogenic molecules along with the antiangiogenic molecules as well. If exogenous introduction of the antiangiogenic substances, to the body, is done to balance over angiogenic molecules, tumor...

  • Anti-Angiogenic Therapy as a Cancer Treatment Paradigm. Dhanabal, Mohanraj; Jeffers, Mike; LaRochelle, William J. // Current Medicinal Chemistry - Anti-Cancer Agents;Mar2005, Vol. 5 Issue 2, p115 

    The inhibition of angiogenesis is an emerging therapeutic strategy for cancer treatment. In contrast to conventional therapies, anti-angiogenic therapies primarily target tumor-associated endothelial cells which serve as a lifeline for tumor growth, progression and metastasis. By blocking the...

  • Gossypiboma treated by colonoscopy. Hinrichs, Clay; Methratta, Sosamma; Ybasco, Albert C. // Pediatric Radiology;Apr2003, Vol. 33 Issue 4, p261 

    Gossypibomas are an unusual postoperative complication and are reluctantly reported in the literature. In the past, the patient would require a laparotomy. More recently, they have been treated laparoscopically and percutaneously by interventional radiology. This is the first case report of a...

  • Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. A. Italiano; C. Massard; R. Bahleda; A.-L. Vataire; E. Deutsch; N. Magné; J.-P. Pignon; G. Vassal; J.-P. Armand; J.-C. Soria // Annals of Oncology;Apr2008, Vol. 19 Issue 4, p787 

    Background: The oncology community usually perceives phase I oncology trials as associated with poor or limited benefits and substantial risks. There is scarce data concerning outcome and survival of patients enrolled in current phase I oncology trials. Patients and methods: We reviewed all...

  • Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango. Thijssen, Victor L. J. L.; van Beijnum, Judy R.; Mayo, Kevin H.; Griffioen, Arjan W. // Current Pharmaceutical Design;Dec2007, Vol. 13 Issue 35, p3576 

    The development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on...

  • Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology. Verhoef, C.; de Wilt, J. H.W.; Verheul, H. M.W. // Current Pharmaceutical Design;Jul2006, Vol. 12 Issue 21, p2623 

    In the past decade, many angiogenesis inhibitors have been developed for clinical use in oncology. Surgeons, radiotherapists as well as medical oncologists have been investigating with much effort and enthusiasm the translation of these agents from the preclinical setting into treatment...

  • Tumor-starving protein identified. Gonzalez, Jennifer; Walsh, Joseph // PharmaGenomics;Jul/Aug2004, Vol. 4 Issue 6, p12 

    The article cites a study conducted by William R. Schiemann and other researchers at the National Jewish Medical and Research Center. They have identified a protein that shows promise as a cancer treatment. The protein fibulin-5 inhibits the formation of new blood vessels that feed and enlarge...

Share

Other Topics